长链非编码RNA在卵巢癌增殖和侵袭中的作用机制

doi:10.12280/gjfckx.20211187

摘要/Abstract

摘要：

卵巢癌是妇科较为常见的恶性肿瘤之一,发病率较高,仅次于宫颈癌和子宫内膜癌。大多数卵巢癌患者确诊时已是中晚期。研究显示,长链非编码RNA（long non-coding RNA,lncRNA）在调控卵巢癌的进展尤其是增殖侵袭中发挥着重要作用。多种lncRNA在卵巢癌组织和细胞中高表达或低表达,通过调控下游信号通路、分子海绵作用激活下游靶向分子、调控蛋白的表达等方式促进或抑制卵巢癌的增殖侵袭。敲除或沉默高表达的lncRNA能抑制卵巢癌的增殖侵袭,这些都可能是卵巢癌诊断和治疗的靶点。有些lncRNA还与卵巢癌的分期、淋巴结转移、生存期等预后因素相关,其也可能是预测预后和结局的标志物。综述lncRNA在卵巢癌增殖侵袭中的作用机制,以期为卵巢癌的诊断和靶向治疗提供依据。

关键词: 卵巢肿瘤, RNA,长链非编码, 细胞增殖, 肿瘤侵润, 防御机制

Abstract:

Ovarian cancer is one of the most common gynecological malignancies with a high incidence, second only to cervical cancer and endometrial cancer. Most ovarian cancer patients are diagnosed in the middle or late stages. Studies have shown that long non-coding RNA (lncRNA) plays an important role in regulating the progression of ovarian cancer, especially the proliferation and invasion. The varieties of lncRNA are overexpressed or underexpressed in ovarian cancer tissues and cells, and the proliferation and invasion of ovarian cancer can be promoted or inhibited by regulating downstream signaling pathways, molecular sponge activating downstream target molecules and regulating protein expression. Knockout or silencing of lncRNAs with high expression can inhibit the proliferation and invasion of ovarian cancer, which may be a target for diagnosis and treatment of ovarian cancer. Some lncRNAs are also associated with ovarian cancer stage, lymph node metastasis, survival and other prognostic factors, which may be prognostic and outcome markers. The mechanism of lncRNA in proliferation and invasion of ovarian cancer was reviewed in order to provide evidence for diagnosis and targeted therapy of ovarian cancer.

Key words: Ovarian neoplasms, RNA, long non-coding, Cell proliferation, Neoplasm invasiveness, Defense mechanisms

张丁丁, 梁敬青, 谷楠楠, 刘素芬. 长链非编码RNA在卵巢癌增殖和侵袭中的作用机制[J]. 国际妇产科学杂志, 2022, 49(4): 376-381.

ZHANG Ding-ding, LIANG Jing-qing, GU Nan-nan, LIU Su-fen. The Mechanism of LncRNA in the Proliferation and Invasion of Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2022, 49(4): 376-381.

参考文献 35

[1]	李艺, 祝洪澜, 昌晓红, 等. 初诊晚期上皮性卵巢癌的规范化治疗[J]. 现代妇产科进展, 2020, 29(10):778-787. doi: 10.13283/j.cnki.xdfckjz.2020.10.011. doi: 10.13283/j.cnki.xdfckjz.2020.10.011
[2]	余敏华, 金明珠, 狄文. PARP抑制剂卵巢癌治疗研究进展[J]. 现代妇产科进展, 2021, 30(6):470-474. doi: 10.13283/j.cnki.xdfckjz.2021.06.017. doi: 10.13283/j.cnki.xdfckjz.2021.06.017
[3]	Xu H, Wang L, Jiang X. Silencing of lncRNA DLEU1 inhibits tumorigenesis of ovarian cancer via regulating miR-429/TFAP2A axis[J]. Mol Cell Biochem, 2021, 476(2):1051-1061. doi: 10.1007/s11010-020-03971-9. doi: 10.1007/s11010-020-03971-9
[4]	Tong L, Wang Y, Ao Y, et al. CREB1 induced lncRNA HAS2-AS1 promotes epithelial ovarian cancer proliferation and invasion via the miR-466/RUNX2 axis[J]. Biomed Pharmacother, 2019, 115:108891. doi: 10.1016/j.biopha.2019.108891. doi: 10.1016/j.biopha.2019.108891
[5]	Liu B, Luo C, Lin H, et al. Long Noncoding RNA XIST Acts as a ceRNA of miR-362-5p to Suppress Breast Cancer Progression[J]. Cancer Biother Radiopharm, 2021, 36(6):456-466. doi: 10.1089/cbr.2019.3481. doi: 10.1089/cbr.2019.3481
[6]	Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2017, 21(17):3850-3856.
[7]	Hua Q, Mi B, Xu F, et al. Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis[J]. Theranostics, 2020, 10(11):4762-4778. doi: 10.7150/thno.43839. doi: 10.7150/thno.43839
[8]	Li T, Liu N, Gao Y, et al. Long noncoding RNA HOTAIR regulates the invasion and metastasis of prostate cancer by targeting hepaCAM[J]. Br J Cancer, 2021, 124(1):247-258. doi: 10.1038/s41416-020-01091-1. doi: 10.1038/s41416-020-01091-1
[9]	He X, Yu B, Kuang G, et al. Long noncoding RNA DLEU2 affects the proliferative and invasive ability of colorectal cancer cells[J]. J Cancer, 2021, 12(2):428-437. doi: 10.7150/jca.48423. doi: 10.7150/jca.48423
[10]	Li T, Chen Y, Zhang J, et al. LncRNA TUG1 promotes cells proliferation and inhibits cells apoptosis through regulating AURKA in epithelial ovarian cancer cells[J]. Medicine(Baltimore), 2018, 97(36):e12131. doi: 10.1097/MD.0000000000012131. doi: 10.1097/MD.0000000000012131
[11]	Liu S, Liu Y, Lu Q, et al. The lncRNA TUG1 promotes epithelial ovarian cancer cell proliferation and invasion via the WNT/β-catenin pathway[J]. Onco Targets Ther, 2018, 11:6845-6851. doi: 10.2147/OTT.S167900. doi: 10.2147/OTT.S167900
[12]	Zhan FL, Chen CF, Yao MZ. LncRNA TUG1 facilitates proliferation, invasion and stemness of ovarian cancer cell via miR-186-5p/ZEB1 axis[J]. Cell Biochem Funct, 2020, 38(8):1069-1078. doi: 10.1002/cbf.3544. doi: 10.1002/cbf.3544
[13]	Yu M, Zhan J, Zhang HQ. HOX family transcription factors: Related signaling pathways and post-translational modifications in cancer[J]. Cell Signal, 2020, 66:109469. doi: 1016/j.cellsig.2019.109469. doi: 1016/j.cellsig.2019.109469
[14]	Xu S, Jia G, Zhang H, et al. LncRNA HOXB-AS3 promotes growth, invasion and migration of epithelial ovarian cancer by altering glycolysis[J]. Life Sci, 2021, 264:118636. doi: 10.1016/j.lfs.2020.118636. doi: 10.1016/j.lfs.2020.118636
[15]	Zhang Y, Dun Y, Zhou S, et al. LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells proliferation and invasion by targeting miR-133a-3p and activating Wnt/β-catenin signaling pathway[J]. Biomed Pharmacother, 2017, 96:1216-1221. doi: 10.1016/j.biopha.2017.11.096. doi: S0753-3322(17)34468-2 pmid: 29239819
[16]	Goyal B, Yadav SRM, Awasthee N, et al. Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2): 188502. doi: 10.1016/j.bbcan.2021.188502. doi: 10.1016/j.bbcan.2021.188502
[17]	Liao H, Chen Q, Xiao J. Reflections on the role of MALAT1 in gynecological cancer[J]. Cancer Manag Res, 2020, 12:13489-13500. doi: 10.2147/CMAR.S286804. doi: 10.2147/CMAR.S286804
[18]	Sun Q, Li Q, Xie F. LncRNA-MALAT1 regulates proliferation and apoptosis of ovarian cancer cells by targeting miR-503-5p[J]. Onco Targets Ther, 2019, 12:6297-6307. doi: 10.2147/OTT.S214689. doi: 10.2147/OTT.S214689
[19]	Jin Y, Feng SJ, Qiu S, et al. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway[J]. Eur Rev Med Pharmacol Sci, 2017, 21(14):3176-3184.
[20]	Li S, Li J, Chen C, et al. Pan-cancer analysis of long non-coding RNA NEAT1 in various cancers[J]. Genes Dis, 2017, 5(1):27-35. doi: 10.1016/j.gendis.2017.11.003. doi: 10.1016/j.gendis.2017.11.003
[21]	Yuan J, Yi K, Yang L. LncRNA NEAT1 promotes proliferation of ovarian cancer cells and angiogenesis of co-incubated human umbilical vein endothelial cells by regulating FGF9 through sponging miR-365: An experimental study[J]. Medicine(Baltimore), 2021, 100(3):e23423. doi: 10.1097/MD.0000000000023423. doi: 10.1097/MD.0000000000023423
[22]	Yin L, Wang Y. Long non-coding RNA NEAT1 facilitates the growth,migration,and invasion of ovarian cancer cells via the let-7g/MEST/ATGL axis[J]. Cancer Cell Int, 2021, 21(1):437. doi: 10.1186/s12935-021-02018-3. doi: 10.1186/s12935-021-02018-3
[23]	Pang B, Sui S, Wang Q, et al. Upregulation of DLEU1 expression by epigenetic modification promotes tumorigenesis in human cancer[J]. J Cell Physiol, 2019, 234(10):17420-17432. doi: 10.1002/jcp.28364. doi: 10.1002/jcp.28364
[24]	Xu C, Zhu LX, Sun DM, et al. Regulatory mechanism of lncRNA NORAD on proliferation and invasion of ovarian cancer cells through miR-199a-3p[J]. Eur Rev Med Pharmacol Sci, 2020, 24(4):1672-1681. doi: 10.26355/eurrev_202002_20341. doi: 10.26355/eurrev_202002_20341
[25]	Tong LL, Ao Y, Zhang HJ, et al. Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR-155-5p[J]. Cancer Med, 2019, 8(10):4782-4791. doi: 10.1002/cam4.2350. doi: 10.1002/cam4.2350
[26]	Mu Y, Li N, Cui YL. The lncRNA CCAT1 upregulates TGFβR1 via sponging miR-490-3p to promote TGFβ1-induced EMT of ovarian cancer cells[J]. Cancer Cell Int, 2018, 18:145. doi: 10.1186/s12935-018-0604-1. doi: 10.1186/s12935-018-0604-1
[27]	Lai XJ, Cheng HF. LncRNA colon cancer-associated transcript 1 (CCAT1) promotes proliferation and metastasis of ovarian cancer via miR-1290[J]. Eur Rev Med Pharmacol Sci, 2018, 22(2):322-328. doi: 10.26355/eurrev_201801_14175. doi: 10.26355/eurrev_201801_14175
[28]	Sun NX, Ye C, Zhao Q, et al. Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing e-cadherin in cervical cancer[J]. PLoS One, 2014, 9(7):e100340. doi: 10.1371/journal.pone.0100340. doi: 10.1371/journal.pone.0100340
[29]	Xu QF, Tang YX, Wang X. LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients[J]. Eur Rev Med Pharmacol Sci, 2018, 22(14):4440-4447. doi: 10.26355/eurrev_ 201807_15495. doi: 10.26355/eurrev_ 201807_15495
[30]	Tao P, Yang B, Zhang H, et al. The overexpression of lncRNA MEG3 inhibits cell viability and invasion and promotes apoptosis in ovarian cancer by sponging miR-205-5p[J]. Int J Clin Exp Pathol, 2020, 13(5):869-879.
[31]	Wang J, Xu W, He Y, et al. LncRNA MEG3 impacts proliferation, invasion, and migration of ovarian cancer cells through regulating PTEN[J]. Inflamm Res, 2018, 67(11/12):927-936. doi: 10.1007/s00011-018-1186-z. doi: 10.1007/s00011-018-1186-z
[32]	Jiang R, Zhang H, Zhou J, et al. Inhibition of long non-coding RNA XIST upregulates microRNA-149-3p to repress ovarian cancer cell progression[J]. Cell Death Dis, 2021, 12(2):145. doi: 10.1038/s41419-020-03358-0. doi: 10.1038/s41419-020-03358-0 pmid: 33542185
[33]	Wang CH, Qi S, Xie C, et al. Upregulation of long non-coding RNA XIST has anticancer effects on epithelial ovarian cancer cells through inverse downregulation of has-miR-214-3p[J]. J Gynecol Oncol, 2018, 29(6):e99. doi: 10.3802/jgo.2018.29.e99. doi: 10.3802/jgo.2018.29.e99
[34]	Guo T, Yuan D, Zhang W, et al. Upregulation of long noncoding RNA XIST has anticancer effects on ovarian cancer through sponging miR-106a[J]. Hum Cell, 2021, 34(2):579-587. doi: 10.1007/s13577-020-00469-w. doi: 10.1007/s13577-020-00469-w
[35]	Cui K, Zhu G. LncRNA CTBP1-AS2 regulates miR-216a/ PTEN to suppress ovarian cancer cell proliferation[J]. J Ovarian Res, 2020, 13(1):84. doi: 10.1186/s13048-020-00689-6. doi: 10.1186/s13048-020-00689-6